Which drugs are FDA approved for treatment of tardive dyskinesia (TD)?

Updated: Oct 17, 2018
  • Author: James Robert Brasic, MD, MPH; Chief Editor: Selim R Benbadis, MD  more...
  • Print


Since these guidelines were last issued, the FDA has approved valbenazine (Ingrezza), the first drug to treat tardive dyskinesia. Valbenazine is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. These drugs modulate the presynaptic packaging and release of dopamine into the synapse, and may offset the movement-related effects of antipsychotics and other dopaminergic blockers. Approval was based on the KINECT 3 trial that included patients with schizophrenia, schizoaffective disorder, or a mood disorder who had moderate or severe tardive dyskinesia. Of the 225 participants, 205 completed the study. Based on the AIMS dyskinesia score, results showed valbenazine significantly improved tardive dyskinesia compared with placebo. [59]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!